Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection.
about
Waging war against uropathogenic Escherichia coli: winning back the urinary tractA conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility.Aberrant community architecture and attenuated persistence of uropathogenic Escherichia coli in the absence of individual IHF subunits.Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infectionBiofilm Formation and Quorum-Sensing-Molecule Production by Clinical Isolates of Serratia liquefaciens.DNABII proteins play a central role in UPEC biofilm structureDefining genomic islands and uropathogen-specific genes in uropathogenic Escherichia colicomplex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coliSignature-tagged mutagenesis and co-infection studies demonstrate the importance of P fimbriae in a murine model of urinary tract infectionLead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosidesExpression and Purification of the Uropathogenic Escherichia coli PapG Protein and its Surface Absorption on Lactobacillus reuteri: Implications for Surface Display System Vaccines.A Phase-Variable Surface Layer from the Gut Symbiont Bacteroides thetaiotaomicronDecreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli reduces urinary tract infection.Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.Regulation of fim genes in uropathogenic Escherichia coli.Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.Treatment and prevention of urinary tract infection with orally active FimH inhibitors.Origins and virulence mechanisms of uropathogenic Escherichia coliMapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study.Rising Cellular Immune Response after Injection of pVax/iutA: A Genetic DNA Cassette as Candidate Vaccine against Urinary Tract Infection.Bacterial Surfaces: Front Lines in Host-Pathogen Interaction.Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.A Role for FimH in Extraintestinal Pathogenic Escherichia coli Invasion and Translocation through the Intestinal Epithelium.Detection of pap, sfa, afa, foc, and fim Adhesin-Encoding Operons in Uropathogenic Escherichia coli Isolates Collected From Patients With Urinary Tract InfectionRegulation of P-fimbrial phase variation frequencies in Escherichia coli CFT073.Evaluation of CpxRA as a Therapeutic Target for Uropathogenic Escherichia coli Infections.Temporal Regulation of fim Genes in Uropathogenic Escherichia coli during Infection of the Murine Urinary Tract.
P2860
Q33613902-CD9F05B8-021D-465A-BD29-2A5DD6ABB735Q34298360-E7309DA3-96E9-44A5-AC2A-E675A610B8C2Q34469467-D5C715CF-9EE3-4A9A-B05E-F0E212215C8EQ35074374-1A1DDCA1-3524-453C-B623-E43866D4FCF5Q35529828-BD326688-E110-4948-B82A-262ABEEF7AD6Q35732611-23D82F27-55F7-465B-938A-16DE3E13E24EQ35759768-F9B172A3-C25F-430E-97A7-A7F9E885A7C5Q35949236-662BAF9E-F46B-4170-9FD5-04AB5324D7AFQ35974546-CA74DF70-FA4E-4875-AF96-79CE6718C51CQ36032748-08874F95-6555-4163-8DF2-FCBF3223034AQ36171857-6785BC92-E3B0-4930-80FF-E9E227C77E84Q36177545-BD9C0EAE-7A68-4BAF-8C32-ADDFA2D6450AQ36211098-6BC84E06-4EFE-480D-AEE2-FFCD2CC5C09FQ36211104-89EF0157-09DE-45EF-8626-6D952F79A0A5Q36802922-768E6948-6FD1-4229-9A14-CE7C59786689Q36910650-C227571B-FB07-4AC1-84D9-39E4366632AFQ36933039-C148C43B-0912-4777-90F1-FEAF08B9D4A2Q36961034-9E1C7FDB-DF05-482F-B1E7-927F57AACF13Q36998104-250FBBF9-D5A5-44D8-83C6-8ADA555DB6F7Q37120109-7D7D85AB-62CE-43F5-AB01-E5EEA472560DQ37165905-5A2FF220-AE20-4E2D-BBD6-A0A004F6645FQ38837720-0DA1BE36-2C9D-46B6-886A-458534AD7EB9Q39307431-40DC474F-7470-46DD-9973-587CAE334D4CQ40083163-2D82B93D-F767-47C3-B165-CB53B00D75CEQ40953838-2E35EB57-13A1-4C79-94C6-EBEC6C8E9C5CQ42432445-2AF5C94B-F688-4359-9AC5-6ECFC15455E1Q48546842-6E39F192-5583-43B5-9C14-DECFE1371C4EQ49513869-48FAEDB6-5924-405A-B897-9685402D0A67
P2860
Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Role of phase variation of typ ...... uring urinary tract infection.
@ast
Role of phase variation of typ ...... uring urinary tract infection.
@en
Role of phase variation of typ ...... uring urinary tract infection.
@nl
type
label
Role of phase variation of typ ...... uring urinary tract infection.
@ast
Role of phase variation of typ ...... uring urinary tract infection.
@en
Role of phase variation of typ ...... uring urinary tract infection.
@nl
prefLabel
Role of phase variation of typ ...... uring urinary tract infection.
@ast
Role of phase variation of typ ...... uring urinary tract infection.
@en
Role of phase variation of typ ...... uring urinary tract infection.
@nl
P2093
P2860
P1476
Role of phase variation of typ ...... uring urinary tract infection.
@en
P2093
Amanda L Lloyd
C Virginia Lockatell
David E Johnson
Jennifer A Snyder
P2860
P304
P356
10.1128/IAI.74.2.1387-1393.2006
P407
P577
2006-02-01T00:00:00Z